As previously mentioned, CXCL8-induced migration of endothelial cells and the growth, proliferation, and migration of tumor cells as well as the chemotaxis of CTCs to the metastases can all be abrogated by neutralizing antibodies of CXCL8/CXCR1/CXCR2 or small-molecule receptor antagonists of CXCR1/CXCR2, indicating that directly targeting CXCL8-CXCR1/2 signaling is critical to controlling the CXCL8-mediated CRC progression. This evidence concerns the gene CXCR1 and colorectal carcinoma.